查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1813354

脫發表觀遺傳學市場預測（至 2032 年）：按產品、作用機制、通路、應用、最終用戶和地區進行的全球分析

Hair Loss Epigenetics Market Forecasts to 2032 - Global Analysis By Product (Epigenetic Drugs, Epigenetic Modulators, Diagnostic Kits & Assays and Other Products), Mechanism of Action, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球脫髮進行觀遺傳學市場預計在 2025 年達到 24 億美元，到 2032 年將達到 66 億美元，預測期內的複合年成長率為 15.9%。

脫髮進行觀遺傳學是指研究表觀遺傳修飾（DNA序列未發生改變的可遺傳基因基因表現變化）如何影響毛髮生長、維持和脫髮。這些修飾包括DNA甲基化、組蛋白修飾和非編碼RNA活性，它們會影響負責毛囊發育、循環和再生的基因活性。環境因素、壓力、飲食和荷爾蒙變化都可能導致表觀遺傳學變化，進而導致男性脫髮症和斑禿脫髮症疾病。了解脫髮觀念遺傳學為透過調節基因表現來預防或逆轉脫髮的標靶治療奠定了基礎。

表觀遺傳學研究進展

表觀遺傳學的快速發展推動了脫髮治療領域的創新。在闡明DNA甲基化、組蛋白修飾和非編碼RNA機制方面的突破，使得針對毛囊再生的精準干預成為可能。這些進展正在推動新型非侵入性治療方法的發展，這些方法可以在不改變DNA序列的情況下調節基因表現。隨著研究機構和生技公司對錶觀遺傳途徑的關注度不斷提高，該市場的專利活動和臨床試驗數量激增，增強了其長期成長動能。

醫療費用高昂

脫發表觀遺傳學市場面臨著巨大的挑戰，因為治療費用高昂，這構成了推廣應用的重大障礙。昂貴的治療方法限制了更廣泛的患者群體，並減緩了市場滲透。這種經濟負擔阻礙了潛在消費者尋求先進的表觀遺傳學解決方案，最終限制了收益成長。因此，規模較小的公司難以競爭，阻礙了整體市場的擴張，也阻礙了創新脫髮療法的廣泛應用。

掉髮盛行率不斷上升

受人口老化、壓力、荷爾蒙失衡和環境因素的影響，全球脫髮病例激增，對創新解決方案的需求也日益旺盛。表觀遺傳療法透過從分子層面解決根本原因，提供了一種變革性的方法。隨著消費者意識的提升和個人化醫療的興起，市場有望從早期診斷和預防性介入中獲益。脫髮盛行率的上升，加上生活方式導致的脫髮，為可擴展的非侵入性表觀遺傳療法帶來了極具吸引力的機會。

監管挑戰

監管挑戰對脫髮進行觀遺傳學市場的成長構成了重大障礙。嚴格的核准流程、複雜的合規要求以及法規的地區差異，導致產品上市延遲並增加營運成本。這些障礙限制了創新治療方法的進入，限制了市場擴張，並阻礙了投資。因此，企業面臨時間延長和不確定性增加的問題，阻礙了研發和整體市場的成長，並扼殺了該領域的潛力。

COVID-19的影響

新冠疫情嚴重擾亂了脫髮發表觀遺傳學市場，實驗室關閉和准入限制導致臨床試驗、研究活動和產品發布延遲。供應鏈中斷影響了關鍵原料的供應，消費支出減少限制了市場需求。此外，醫療資源被轉移用於應對疫情，減緩了脫髮治療領域的創新和投資。整體而言，新冠疫情導致市場成長出現暫時但顯著的放緩。

DNA甲基化抑制劑市場預計將在預測期內佔據最大佔有率

DNA甲基化抑制劑領域預計將在預測期內佔據最大的市場佔有率，這得益於其在重新運作毛囊再生中沉默基因方面的關鍵作用。這些化合物針對破壞正常毛髮週期的異常甲基化模式，為逆轉男性脫髮症等疾病提供了一條充滿希望​​的途徑。隨著臨床檢驗的進展和治療管線的不斷擴展，該領域正在吸引生物技術公司的大量投資。它們的擴充性、與局部給藥系統的兼容性以及聯合治療的潛力進一步鞏固了其市場領先地位。

預計脫髮症領域在預測期內將出現最高的複合年成長率。

由於斑禿脫髮症不斷上升且醫療需求尚未滿足，預計該領域將在預測期內實現最高成長率。脫髮症的特徵是自體免疫介導的毛囊攻擊，表觀遺傳修飾策略對恢復免疫耐受性和促進毛髮生長反應良好。針對組蛋白乙醯化和非編碼RNA路徑的新型治療方法在早期臨床試驗中已顯示出良好的療效。隨著認知度的提高和診斷準確性的提高，該領域有望從有針對性的干涉措施和個人化治療通訊協定中受益。

佔比最高的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率，這得益於其龐大的人口、不斷成長的可支配收入以及日益增強的毛髮健康意識。中國、日本和韓國等國家正大力投資生技創新和個人化醫療。此外，對美髮美學的文化重視以及不斷擴展的皮膚科基礎設施正在加速此類療法的普及。區域和全球公司之間的策略合作夥伴關係正在進一步提升不同消費群體獲得先進表觀遺傳療法的管道。

複合年成長率最高的地區：

預計北美將在預測期內呈現最高的複合年成長率，這得益於其強大的研發生態系統、良好的監管途徑以及消費者採用最先進治療的強烈意願。該地區受益於強大的產學合作，加速了表觀遺傳學發現轉化為商業性治療的影響。壓力相關脫髮和自體免疫疾病的增加刺激了精準醫療的需求。創業投資的流入和FDA簡審類進一步推動了技術創新，使北美成為關鍵的成長引擎。

免費客製化服務：

此報告的訂閱者可以選擇以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球脫發表觀遺傳學市場（按產品）

  • 表觀遺傳藥物
  • 表觀遺傳調變器
  • 診斷套件和檢測試劑
  • 其他產品

6. 全球脫發表觀遺傳學市場（依作用機制）

  • DNA甲基化抑制劑
  • 組蛋白去乙醯化酶（HDAC）抑制劑
  • 基於RNA的作用機制
  • 其他作用機制

7. 全球脫發表觀遺傳學市場（按分銷管道）

  • 醫院和皮膚科
  • 研究和學術機構
  • 零售藥局
  • 網路藥局

8. 全球脫發表觀遺傳學市場（按應用）

  • 雄性禿（雄性脫毛症脫髮症）
  • 女性型脫髮症
  • 脫髮症
  • 化療引起的脫髮症
  • 其他用途

9. 全球脫發表觀遺傳學市場（按最終用戶）

  • 醫療保健提供者
  • 研究機構
  • 個人消費者
  • 其他最終用戶

第10章全球脫發表觀遺傳學市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第 12 章：公司概況

  • Pelage Pharmaceuticals
  • RepliCel Life Sciences
  • Amplifica Bio
  • Stemson Therapeutics
  • Silab
  • L'Oreal
  • Shiseido
  • TruDiagnostic
  • Chroma Medicine
  • Omega Therapeutics
  • Storm Therapeutics
  • K36 Therapeutics
  • Inherent Biosciences
  • EpigenCare
  • Epibiotech
Product Code: SMRC30801

According to Stratistics MRC, the Global Hair Loss Epigenetics Market is accounted for $2.4 billion in 2025 and is expected to reach $6.6 billion by 2032 growing at a CAGR of 15.9% during the forecast period. Hair loss epigenetics refers to the study of how epigenetic modifications-heritable changes in gene expression that do not involve alterations to the DNA sequence-affect the growth, maintenance, and shedding of hair. These modifications include DNA methylation, histone modification, and non-coding RNA activity, which can influence the activity of genes responsible for hair follicle development, cycling, and regeneration. Environmental factors, stress, diet, and hormonal changes can trigger epigenetic alterations, leading to conditions such as androgenetic alopecia or alopecia areata. Understanding hair loss epigenetics opens avenues for targeted therapies that modulate gene expression to prevent or reverse hair thinning.

Market Dynamics:

Driver:

Advancements in Epigenetic Research

Rapid progress in epigenetic science is catalyzing innovation in hair loss therapeutics. Breakthroughs in understanding DNA methylation, histone modification, and non-coding RNA mechanisms are enabling precision-targeted interventions for follicular regeneration. These advancements are driving the development of novel, non-invasive treatments that modulate gene expression without altering DNA sequences. As research institutions and biotech firms intensify their focus on epigenetic pathways, the market is witnessing a surge in patent activity and clinical trials, reinforcing long-term growth momentum.

Restraint:

High Treatment Costs

The Hair Loss Epigenetics Market faces significant challenges due to high treatment costs, which act as a major barrier to adoption. Expensive therapies limit accessibility for a broader patient base, slowing market penetration. This financial burden discourages potential consumers from seeking advanced epigenetic solutions, ultimately restraining revenue growth. As a result, smaller players struggle to compete, while overall market expansion is hindered, impeding widespread acceptance of innovative hair loss treatments.

Opportunity:

Rising Prevalence of Hair Loss

The global surge in hair loss cases-driven by aging populations, stress, hormonal imbalances, and environmental factors-is creating robust demand for innovative solutions. Epigenetic therapies offer a transformative approach by addressing root causes at the molecular level. With increasing consumer awareness and a shift toward personalized medicine, the market is poised to benefit from early diagnostics and preventive interventions. This rising prevalence, coupled with lifestyle-driven hair thinning, presents a compelling opportunity for scalable, non-invasive epigenetic treatments.

Threat:

Regulatory Challenges

Regulatory challenges pose a significant barrier to the growth of the Hair Loss Epigenetics Market. Stringent approval processes, complex compliance requirements, and varying regulations across regions delay product launch and increase operational costs. These hurdles limit the entry of innovative therapies and restrict market expansion, discouraging investment. Consequently, companies face prolonged timelines and heightened uncertainties, which hinder research, development, and overall market growth, stifling the sector's potential.

Covid-19 Impact

The Covid-19 pandemic significantly disrupted the Hair Loss Epigenetics Market, causing delays in clinical trials, research activities, and product launches due to lockdowns and restricted laboratory access. Supply chain interruptions affected the availability of critical raw materials, while reduced consumer spending limited market demand. Additionally, healthcare resources were redirected toward pandemic response, slowing innovation and investment in hair loss treatments. Overall, Covid-19 created a temporary but notable slowdown in market growth.

The DNA methylation inhibitors segment is expected to be the largest during the forecast period

The DNA methylation inhibitors segment is expected to account for the largest market share during the forecast period, due to their pivotal role in reactivating silenced genes involved in hair follicle regeneration. These compounds target aberrant methylation patterns that disrupt normal hair cycling, offering a promising route for reversing conditions like androgenetic alopecia. With growing clinical validation and expanding therapeutic pipelines, this segment is attracting significant investment from biotech firms. Its scalability, compatibility with topical delivery systems, and potential for combination therapies further reinforce its market leadership.

The alopecia areata segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the alopecia areata segment is predicted to witness the highest growth rate, due to increasing incidence and unmet clinical needs. Characterized by autoimmune-mediated follicular attack, alopecia areata responds well to epigenetic modulation strategies that restore immune tolerance and promote hair regrowth. Emerging therapies targeting histone acetylation and non-coding RNA pathways are showing promising results in early trials. As awareness grows and diagnostic precision improves, this segment is set to benefit from targeted interventions and personalized treatment protocols.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to a large population base, rising disposable incomes, and increasing awareness of hair health. Countries like China, Japan, and South Korea are investing heavily in biotech innovation and personalized medicine. Additionally, cultural emphasis on hair aesthetics and expanding dermatology infrastructure are accelerating adoption. Strategic collaborations between regional firms and global players are further enhancing access to advanced epigenetic therapies across diverse consumer segments.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust R&D ecosystems, favorable regulatory pathways, and high consumer willingness to adopt cutting-edge treatments. The region benefits from strong academic-industry collaboration, accelerating the translation of epigenetic discoveries into commercial therapies. With rising prevalence of stress-induced hair loss and autoimmune conditions, demand for precision medicine is surging. Venture capital inflows and FDA fast-track designations are further propelling innovation, positioning North America as a key growth engine.

Key players in the market

Some of the key players profiled in the Hair Loss Epigenetics Market include Pelage Pharmaceuticals, RepliCel Life Sciences, Amplifica Bio, Stemson Therapeutics, Silab, L'Oreal, Shiseido, TruDiagnostic, Chroma Medicine, Omega Therapeutics, Storm Therapeutics, K36 Therapeutics, Inherent Biosciences, EpigenCare and Epibiotech.

Key Developments:

In March 2025, L'Oreal Groupe announced a strategic research and development partnership with TruDiagnostic, a leader in epigenomics testing. This collaboration aims to explore the connection between beauty indicators and changes in epigenomic markers, paving the way for groundbreaking advancements in the field of longevity.

In July 2024, Pelage Pharmaceuticals entered into a new partnership with UCLA Ventures, focusing on advancing regenerative therapies for hair loss. This collaboration aims to leverage UCLA's research capabilities to accelerate the development of Pelage's innovative treatments.

Products Covered:

  • Epigenetic Drugs
  • Epigenetic Modulators
  • Diagnostic Kits & Assays
  • Other Products

Mechanism of Actions Covered:

  • DNA Methylation Inhibitors
  • Histone Deacetylase (HDAC) Inhibitors
  • RNA-based Mechanisms
  • Other Mechanisms

Distribution Channels Covered:

  • Hospitals & Dermatology Clinics
  • Research & Academic Institutes
  • Retail Pharmacies
  • Online Pharmacies

Applications Covered:

  • Male Pattern Baldness (Androgenetic Alopecia)
  • Female Pattern Hair Loss
  • Alopecia Areata
  • Chemotherapy-Induced Hair Loss
  • Other Applications

End Users Covered:

  • Healthcare Providers
  • Research Organizations
  • Individual Consumers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hair Loss Epigenetics Market, By Product

  • 5.1 Introduction
  • 5.2 Epigenetic Drugs
  • 5.3 Epigenetic Modulators
  • 5.4 Diagnostic Kits & Assays
  • 5.5 Other Products

6 Global Hair Loss Epigenetics Market, By Mechanism of Action

  • 6.1 Introduction
  • 6.2 DNA Methylation Inhibitors
  • 6.3 Histone Deacetylase (HDAC) Inhibitors
  • 6.4 RNA-based Mechanisms
  • 6.5 Other Mechanisms

7 Global Hair Loss Epigenetics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospitals & Dermatology Clinics
  • 7.3 Research & Academic Institutes
  • 7.4 Retail Pharmacies
  • 7.5 Online Pharmacies

8 Global Hair Loss Epigenetics Market, By Application

  • 8.1 Introduction
  • 8.2 Male Pattern Baldness (Androgenetic Alopecia)
  • 8.3 Female Pattern Hair Loss
  • 8.4 Alopecia Areata
  • 8.5 Chemotherapy-Induced Hair Loss
  • 8.6 Other Applications

9 Global Hair Loss Epigenetics Market, By End User

  • 9.1 Introduction
  • 9.2 Healthcare Providers
  • 9.3 Research Organizations
  • 9.4 Individual Consumers
  • 9.5 Other End Users

10 Global Hair Loss Epigenetics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pelage Pharmaceuticals
  • 12.2 RepliCel Life Sciences
  • 12.3 Amplifica Bio
  • 12.4 Stemson Therapeutics
  • 12.5 Silab
  • 12.6 L'Oreal
  • 12.7 Shiseido
  • 12.8 TruDiagnostic
  • 12.9 Chroma Medicine
  • 12.10 Omega Therapeutics
  • 12.11 Storm Therapeutics
  • 12.12 K36 Therapeutics
  • 12.13 Inherent Biosciences
  • 12.14 EpigenCare
  • 12.15 Epibiotech

List of Tables

  • Table 1 Global Hair Loss Epigenetics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Hair Loss Epigenetics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Hair Loss Epigenetics Market Outlook, By Epigenetic Drugs (2024-2032) ($MN)
  • Table 4 Global Hair Loss Epigenetics Market Outlook, By Epigenetic Modulators (2024-2032) ($MN)
  • Table 5 Global Hair Loss Epigenetics Market Outlook, By Diagnostic Kits & Assays (2024-2032) ($MN)
  • Table 6 Global Hair Loss Epigenetics Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 7 Global Hair Loss Epigenetics Market Outlook, By Mechanism of Action (2024-2032) ($MN)
  • Table 8 Global Hair Loss Epigenetics Market Outlook, By DNA Methylation Inhibitors (2024-2032) ($MN)
  • Table 9 Global Hair Loss Epigenetics Market Outlook, By Histone Deacetylase (HDAC) Inhibitors (2024-2032) ($MN)
  • Table 10 Global Hair Loss Epigenetics Market Outlook, By RNA-based Mechanisms (2024-2032) ($MN)
  • Table 11 Global Hair Loss Epigenetics Market Outlook, By Other Mechanisms (2024-2032) ($MN)
  • Table 12 Global Hair Loss Epigenetics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 13 Global Hair Loss Epigenetics Market Outlook, By Hospitals & Dermatology Clinics (2024-2032) ($MN)
  • Table 14 Global Hair Loss Epigenetics Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 15 Global Hair Loss Epigenetics Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 16 Global Hair Loss Epigenetics Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 17 Global Hair Loss Epigenetics Market Outlook, By Application (2024-2032) ($MN)
  • Table 18 Global Hair Loss Epigenetics Market Outlook, By Male Pattern Baldness (Androgenetic Alopecia) (2024-2032) ($MN)
  • Table 19 Global Hair Loss Epigenetics Market Outlook, By Female Pattern Hair Loss (2024-2032) ($MN)
  • Table 20 Global Hair Loss Epigenetics Market Outlook, By Alopecia Areata (2024-2032) ($MN)
  • Table 21 Global Hair Loss Epigenetics Market Outlook, By Chemotherapy-Induced Hair Loss (2024-2032) ($MN)
  • Table 22 Global Hair Loss Epigenetics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 23 Global Hair Loss Epigenetics Market Outlook, By End User (2024-2032) ($MN)
  • Table 24 Global Hair Loss Epigenetics Market Outlook, By Healthcare Providers (2024-2032) ($MN)
  • Table 25 Global Hair Loss Epigenetics Market Outlook, By Research Organizations (2024-2032) ($MN)
  • Table 26 Global Hair Loss Epigenetics Market Outlook, By Individual Consumers (2024-2032) ($MN)
  • Table 27 Global Hair Loss Epigenetics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.